Riskpilot← Back to searchSign inGet full accessTESTMED AS
ASActiveOrg 823950152Tallbergveien 2E, 1166 OsloComputer programming activities · NACE 6210Est. 20190 employees
Revenue 2024
NOK 1M
-42% vs 2023
EBITDA margin
-11.2%
-185% vs 2023
Equity ratio
86.9%
Financial strength
Net profit 2024
NOK -120K
-216% vs 2023
| Revenue | NOK 1M | -42% |
| EBITDA | NOK -115K | -185% |
| Net profit | NOK -120K | -216% |
| Total assets | NOK 608K | -18% |
| Equity | NOK 528K | -18% |
| Employees | 0 | — |
Legal name
TESTMED AS
Org number
823950152
Legal form
Aksjeselskap
NACE code
6210 · Computer programming activities
Founded
27. november 2019
Share capital
NOK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Selge varer og konsulenttjenester knyttet til programvareutvikling og testprosjekter. Herunder rådgivning og utvikling av digitale produkter innen helsetjenester, digital strategi, og fornybare energi løsninger, samt investering i andre selskaper - samt annet som naturlig sammenfaller med dette.
Address
Tallbergveien 2E, 1166 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 728 | 1 529 | 1 953 | 1 773 | 1 030 |
| Staff expenses | −3 | −8 | −0 | −0 | −0 |
| EBITDA | 381 | 274 | 255 | 136 | −115 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 381 | 274 | 255 | 136 | −115 |
| Net financials | −0 | −0 | −1 | −4 | −4 |
| Profit before tax | 381 | 274 | 254 | 132 | −120 |
| Tax | 87 | 63 | 56 | 29 | −0 |
| Net profit | 294 | 211 | 198 | 103 | −120 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 472 | 670 | 946 | 745 | 608 |
| Equity | 318 | 529 | 545 | 648 | 528 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 154 | 141 | 402 | 98 | 80 |
| Total debt | 154 | 141 | 402 | 98 | 80 |
EBITDA margin
-11.2%
This company
15.8%
Market median
-171% vs market
20202024
Equity ratio
86.9%
This company
38.2%
Market median
+127% vs market
20202024
Return on equity
-22.6%
This company
18.4%
Market median
-223% vs market
20202024
Net profit margin
-11.6%
This company
8.1%
Market median
-243% vs market
20202024
Asset turnover
1.69×
This company
1.12×
Market median
+51% vs market
20202024
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
OR Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TESTMED AS 
MEDIOTEQ ASBoard members of TESTMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Olga Romenska | Chief Executive Officer | 0 companies |
| Olga Dyngeland | Chairman | 0 companies |